بدائل البحث:
increase decrease » increased release (توسيع البحث), increased crash (توسيع البحث)
greatest decrease » treatment decreased (توسيع البحث), greater increase (توسيع البحث)
weaker decrease » greater decrease (توسيع البحث), teer decrease (توسيع البحث), water decreases (توسيع البحث)
increase decrease » increased release (توسيع البحث), increased crash (توسيع البحث)
greatest decrease » treatment decreased (توسيع البحث), greater increase (توسيع البحث)
weaker decrease » greater decrease (توسيع البحث), teer decrease (توسيع البحث), water decreases (توسيع البحث)
-
1341
DALYs number, ASDR under the age of 20 in 204 countries and territories in 2021.
منشور في 2025الموضوعات: -
1342
-
1343
-
1344
-
1345
-
1346
-
1347
-
1348
-
1349
-
1350
-
1351
Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength.
منشور في 2024الموضوعات: -
1352
-
1353
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
1354
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
1355
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
1356
-
1357
-
1358
-
1359
-
1360